BlackRock Inc. grew its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,605,247 shares of the biopharmaceutical company’s stock after purchasing an additional 195,590 shares during the period. BlackRock Inc. owned about 6.69% of TESARO worth $504,230,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Botty Investors LLC bought a new stake in TESARO during the second quarter worth about $140,000. Meeder Asset Management Inc. bought a new stake in TESARO during the first quarter worth about $177,000. Oppenheimer Asset Management Inc. lifted its stake in TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares during the last quarter. BB&T Securities LLC bought a new stake in TESARO during the second quarter worth about $222,000. Finally, Fox Run Management L.L.C. bought a new stake in TESARO during the second quarter worth about $224,000.

ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Shares Bought by BlackRock Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/25/tesaro-inc-tsro-shares-bought-by-blackrock-inc.html.

TESARO, Inc. (TSRO) opened at 119.04 on Monday. TESARO, Inc. has a one year low of $96.52 and a one year high of $192.94. The company’s 50-day moving average price is $121.03 and its 200-day moving average price is $138.94. The stock’s market cap is $6.45 billion.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.28) EPS. Analysts forecast that TESARO, Inc. will post ($8.61) EPS for the current fiscal year.

Several brokerages have issued reports on TSRO. Cann reissued a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. Citigroup Inc. reissued a “buy” rating and issued a $216.00 target price on shares of TESARO in a research note on Monday, September 11th. Robert W. Baird reissued a “neutral” rating and issued a $140.00 target price (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Cowen and Company lowered their target price on TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a research note on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $171.42.

In other news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last three months, insiders sold 35,100 shares of company stock valued at $4,558,765. 34.60% of the stock is owned by insiders.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.